a year ago
BSX
AnalystsMike KratkyMike Kratky's Stock Forecasts
AnalystsMike Kratky
Analyst Ranking
Top 17%
#874 out of 5278 analysts
Average Return
+20.3%
Win Rate
43%13 out of 30
Risk vs Reward
Poor
Good
Mike Kratky's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Axogen IncAXGN | +242.48% | $4.19 | $14.35 | 2023-10-16 - 2024-10-15 | Buy |
Immunovant IncIMVT | +182.07% | $12.05 | $33.99 | 2022-11-04 - 2023-11-03 | Buy |
Procept Biorobotics CorpPRCT | +144.24% | $29.52 | $72.10 | 2023-10-16 - 2024-10-15 | Buy |
Morphic Holding IncMORF | +109.25% | $26.27 | $54.97 | 2022-07-20 - 2023-07-19 | Buy |
Intuitive Surgical IncISRG | +74.52% | $274.16 | $478.47 | 2023-10-16 - 2024-10-15 | Buy |
Mike Kratky Analyst Color
Get additional color on Mike Kratky's coverage of popular stocks
Mike Kratky's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Intuitive Surgical IncISRG | 2 | Buy | $573.00 | +36.07% | Maintains | 25 days ago |
Beta Bionics IncBBNX | 2 | Buy | $24.00 | +153.70% | Maintains | 25 days ago |
Zimmer Biomet Holdings IncZBH | 1 | Hold | $101.00 | +20.67% | Initiates Coverage On | a month ago |
Stryker CorpSYK | 1 | Buy | $410.00 | +33.65% | Initiates Coverage On | a month ago |
Procept Biorobotics CorpPRCT | 2 | Buy | $30.00 | +14.85% | Maintains | 3 months ago |
Insulet CorpPODD | 2 | Buy | $360.00 | +144.13% | Maintains | 3 months ago |
10x Genomics IncTXG | 5 | Hold | $20.00 | -5.66% | Maintains | 4 months ago |
Penumbra IncPEN | 2 | Hold | $374.00 | +16.03% | Downgrades | 4 months ago |
Boston Scientific CorpBSX | 2 | Buy | $128.00 | +142.98% | Maintains | 8 months ago |
Inspire Medical Systems IncINSP | 7 | Hold | $97.00 | +142.20% | Maintains | 9 months ago |
Medtronic PLCMDT | 1 | Buy | $110.00 | +44.45% | Initiates Coverage On | a year ago |
Dexcom IncDXCM | 2 | Buy | $87.00 | N/A | Maintains | 2 years ago |
Inari Medical IncNARI | 1 | Hold | $47.00 | N/A | Initiates Coverage On | 2 years ago |
Tandem Diabetes Care IncTNDM | 2 | Buy | $45.00 | N/A | Upgrades | 2 years ago |
Shockwave Medical IncSWAV | 2 | Hold | $335.00 | N/A | Downgrades | 2 years ago |
Neuropace IncNPCE | 1 | Buy | $22.00 | N/A | Initiates Coverage On | 2 years ago |
Axonics IncAXNX | 2 | Hold | $71.00 | N/A | Downgrades | 2 years ago |
Vericel CorpVCEL | 1 | Buy | $42.00 | N/A | Initiates Coverage On | 3 years ago |
Edwards Lifesciences CorpEW | 1 | Hold | $75.00 | N/A | Initiates Coverage On | 3 years ago |
Axogen IncAXGN | 1 | Buy | $9.00 | N/A | Initiates Coverage On | 3 years ago |
Damora Therapeutics IncDMRA | 2 | Hold | $50.00 | N/A | Downgrades | 3 years ago |
Pliant Therapeutics IncPLRX | 2 | Buy | $45.00 | N/A | Maintains | 3 years ago |
Madrigal Pharmaceuticals IncMDGL | 1 | Buy | $315.00 | N/A | Maintains | 3 years ago |
Axcella Health IncAXLA | 1 | Hold | $50.00 | N/A | Downgrades | 3 years ago |
Kymera Therapeutics IncKYMR | 2 | Hold | $31.00 | N/A | Maintains | 3 years ago |
Immunovant IncIMVT | 1 | Buy | $14.00 | N/A | Maintains | 4 years ago |
Viridian Therapeutics IncVRDN | 1 | Buy | $40.00 | N/A | Maintains | 4 years ago |
Rapt Therapeutics IncRAPT | 1 | Buy | $384.00 | N/A | Maintains | 4 years ago |
Morphic Holding IncMORF | 1 | Buy | $45.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.